Two posters presented at the 2025 American Academy of Dermatology Annual Meeting highlighted the importance of improving ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

Topline results from Phase 3 ICONIC-ADVANCE 1&2�studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO ...

Since revealing her plaque psoriasis diagnosis in 2015, La La Anthony has become a powerful voice for those living with the chronic skin condition. Plaque psoriasis-often mistaken for dry skin or ...

Accessed March 2025. 8 Clinicaltrials.gov. A study of JNJ-2113 for the treatment of participants with plaque psoriasis involving special areas (scalp, genital, and/or palms of the hands and the soles ...

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD studyTopline results from Phase ...

according to the analysis of patients with plaque psoriasis. “We typically don’t think about putting cream on the scalp,” she added, but additional research looking at this PAD-formulated ...

ZORYVE cream, 0.3%, is indicated for topical treatment of plaque psoriasis ... based on the PDUFA for the treatment of scalp and body psoriasis, the potential for clinical results for ZORYVE ...

flaky skin on your scalp. Dandruff typically appears as general flaking, but psoriasis develops from a clearly defined plaque (thick patch of skin). Psoriasis plaques can be white or grey and turn ...

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced new data from two posters ...

"Plaque psoriasis often affects patients more severely than can be measured by body surface area alone, particularly for those with manifestations in difficult-to-treat areas like the scalp," she ...